There is no redundancy
26, 2026: When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes patent fight over semaglutide and what it could mean for the broader multi-billion-dollar market for GLP-1 treatments
Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee only when a pre-qualified patient books with you
You might be getting more or less of an ingredient than you think - or something thats not listed at all
Il BPC-157 accelera la guarigione dei tendini sezionati o danneggiati stimolando la proliferazione dei tenociti, la sintesi di collagene di tipo I e la neovascolarizzazione locale
The abstract does not include the specifics for these endpoints, only stating that there were significant improvements. Eli Lilly previously disclosed in a press release, that they expected patients using tirzepatide to lose between 18-20% of their body weight